Results 31 to 40 of about 4,126 (156)
First results of phase 3 trial of RTS,S/AS01 malaria vaccine in African children. [PDF]
, 2011 BACKGROUND\ud
\ud
An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries.\ud
\ud
METHODS\ud
\ud
From March 2009 through January 2011, we enrolled 15,460 ...Machera, Francisca, Abdulla, Salim, Sillman, Marla, Maingi, Charity, Aide, Pedro, Kremsner, Peter Gottfried, Conzelmann, Cornelia, Adjei, George, Abdul, Omari, Leach, Amanda, Methogo, Barbara Gaelle Nfono Ondo, Bejon, Philip, Gondi, Stacey, Chome, Nelecy, Doucka, Yannick, Aponte, John J, Guerra, Yolanda, Chandramohan, Daniel, null null, Jones, David, Liheluka, Edwin, Loucq, Christian, Omoto, Jackton, Nyakuipa, Dalitso, Flamen, Arnaud, Jongert, Erik, Otieno, Walter, Bassat, Quique, Mordmüller, Benjamin, Slutsker, Laurence, Agyekum, Alex, Ofori-Anyinam, Opokua, Hamad, Ali Said, Wasuna, Ruth, Vansadia, Preeti, Lanaspa, Miguel, Drakeley, Chris, Kaboré, William, Asante, Isaac, Gesase, Samwel, Cohen, Joe, Shubis, Kafuruki, Ogutu, Bernhards, Agnandji, Selidji Todagbe, Otieno, Lucas, Sambian, David, Ansong, Daniel, Lell, Bertrand, Awino, Norbert, Gitaka, Jesse, Carter, Terrell, Juma, Omar, Shomari, Mwanajaa, Hoffman, Irving, Mtoro, Ali, Schellenberg, David, Quelhas, Diana, Radford, Afiya, Minja, Rose, Kerubo, Christine, Theander, Thor, Ahmed, Saumu, Odero, Chris, Vekemans, Johan, Nkomo, Ruthendo, Muturi-Kioi, Vincent, Mvalo, Tisungane, RTS,S Clinical Trials Partnership, Tsofa, Benjamin, Dosoo, David, Ouédraogo, Jean Bosco, Mwangoka, Grace, Rettig, Theresa, Sorgho, Hermann, Ouédraogo, Sayouba, Osei-Kwakye, Kingsley, Agbenyega, Tsiri, Owira, Victorine, Issifou, Saadou, Kariuki, Simon, Oneko, Martina, Otieno, Kephas, Olotu, Ally, Lapierre, Didier, Fernandes, José Francisco, Ali, Ali Mohammed, Boahen, Owusu, Onyango, Agnes Akoth, Sylverken, Justice, Hamel, Mary J, Macete, Eusébio, Asante, Kwaku Poku, Owusu-Agyei, Seth, Lemnge, Martha, Ayamba, Samuel, Msika, Albans, Kayan, Kingsley, Alonso, Pedro, Kamthunzi, Portia, Otieno, Allan, Ballou, W Ripley, Nekoye, Otsyula, Lievens, Marc, Abossolo, Béatrice Peggy, Mandjate, Sofia, Marsh, Kevin, Urassa, Alwisa Martin, Mahende, Coline, Bawa, John, Sandrine, Yara, Akoo, Pauline, Adjei, Samuel, Njuguna, Patricia, Jumbe, Allan, Williamson, John, Leboulleux, Didier, Greenwood, Brian, Malabeja, Anangisye, Chilengi, Roma, Nhamuave, Arlindo, Guiguemdé, Robert Tinga, Tinto, Halidou, Tahita, Marc Christian, Martinson, Francis, Kilavo, Hassan, Lusingu, John, Boateng, Harry Owusu, Chintedza, Joseph, Soulanoudjingar, Solange Solmeheim, Lang, Trudie, Sacarlal, Jahit, Bruls, Myriam, The RTS, S. Clinical Trials Partnership, Sykes, Alma, Owusu, Larko, Tanner, Marcel, Laserson, Kayla F, Peshu, Norbert, Savarese, Barbara, Owusu-Ofori, Ruth, Valea, Innocent, D'Alessandro, Umberto, Salim, Nahya +142 morecore +1 more sourceSafety of the malaria vaccine candidate, RTS,S/AS01E in 5 to 17 month old Kenyan and Tanzanian Children. [PDF]
PLoS ONE, 2010 The malaria vaccine candidate, RTS,S/AS01(E), showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability.John Lusingu, Ally Olotu, Amanda Leach, Marc Lievens, Johan Vekemans, Aurélie Olivier, Sarah Benns, Raimos Olomi, Salum Msham, Trudie Lang, Jayne Gould, Karin Hallez, Yolanda Guerra, Patricia Njuguna, Ken O Awuondo, Anangisye Malabeja, Omar Abdul, Samwel Gesase, Denise Dekker, Lincoln Malle, Sadiki Ismael, Neema Mturi, Chris J Drakeley, Barbara Savarese, Tonya Villafana, W Ripley Ballou, Joe Cohen, Eleanor M Riley, Martha M Lemnge, Kevin Marsh, Philip Bejon, Lorenz von Seidlein +31 moredoaj +1 more sourceDevelopment of standardized laboratory methods and quality processes for a phase III study of the RTS, S/AS01 candidate malaria vaccine. [PDF]
, 2011 BACKGROUND\ud
\ud
A pivotal phase III study of the RTS,S/AS01 malaria candidate vaccine is ongoing in several research centres across Africa. The development and establishment of quality systems was a requirement for trial conduct to meet international ...Ingram, Charlotte, Bruls Myriam, Andrea Reijman, Oyakhirome, Sunny, Swysen, Christine, Drakeley, Chris, Okech Brenda, Frean John, Brenda Okech, Greenwood, Brian, Villafana Tonya, Reijman Andrea, Ogutu Bernhards, Barbara Savarese, Ogutu, Bernhards, Carter Terrell, Greenwood Brian, Opokua Ofori-Anyinam, Drakeley Chris, Sunny Oyakhirome, Clinical Trials Partnership Committee, null null, Carter, Terrell, Adriano Duse, Bernhards Ogutu, Duse, Adriano, Reijman, Andrea, Vekemans Johan, Savarese Barbara, Myriam Bruls, John Frean, Bruls, Myriam, Kremsner, Peter, Oyakhirome Sunny, Chris Drakeley, Ofori-Anyinam Opokua, Brian Greenwood, Vekemans, Johan, Duse Adriano, Peter Kremsner, Savarese, Barbara, Ingram Charlotte, Christine Swysen, Swysen Christine, Frean, John, Terrell Carter, Ofori-Anyinam, Opokua, Charlotte Ingram, Okech, Brenda, Tonya Villafana, Johan Vekemans, Kremsner Peter, Villafana, Tonya +52 morecore +1 more sourceEfficacy and Safety of the RTS,S/AS01 Malaria Vaccine during 18 Months after Vaccination: A Phase 3 Randomized, Controlled Trial in Children and Young Infants at 11 African Sites [PDF]
, 2014 A malaria vaccine could be an important addition to current control strategies. We report the safety and vaccine efficacy (VE) of the RTS,S/AS01 vaccine during 18 mo following vaccination at 11 African sites with varying malaria transmission.; 6,537 ...RTS, S. Clinical Trials Partnership, RTS,S Clinical Trials Partnership, The RTS,S Clinical Trials Partnership (2014) (614272), Issifou, Saadou, Theander, Thor Grundtvig, Fernandes, José Francisco, Kremsner, Peter, Mordmüller, Benjamin Gottlieb, Abossolo, Béatrice Peggy, Kabwende, Anita Lumeka, Agnandji, Selidji Todagbe, Lusingu, John Peter Andrea, Massinga-Loembé, Marguerite, Lell, Bertrand, Adegnika, Ayôla Akim +14 morecore +1 more sourceRTS,S/AS01 vaccine (Mosquirix™): an overview
Human Vaccines & Immunotherapeutics, 2020 Malaria is an illness caused by Plasmodium parasites transmitted to humans by infected mosquitoes. Of the five species that infect humans, P. falciparum exacts the highest toll in terms of human morbidity and mortality, and therefore represents a major ...Matthew B. Laurensdoaj +1 more sourceSimulated impact of RTS,S/AS01 vaccination programs in the context of changing malaria transmission [PDF]
, 2012 INTRODUCTION: The RTS,S/AS01 pre-erythrocytic malaria vaccine is in phase III clinical trials. It is critical to anticipate where and how it should be implemented if trials are successful.Hardy Diggory, Diggory Hardy, Diggory Hardy (179135), Richard Steketee, Olivier J. T. Briët (179129), Richard Steketee (75064), Brooks, A., Smith, T. A., Steketee Richard, Steketee, R., Briët Olivier J. T., Brooks Alan, Hardy, D., Briët, O. J., Olivier J T Briët, Thomas A. Smith (95630), Thomas A Smith, Alan Brooks (179125), Alan Brooks, Smith Thomas A., Smith TA, Hardy D, Brooks A, Steketee R, Briët OJ +24 morecore +2 more sourcesMRI/PET multimodal imaging of the innate immune response in skeletal muscle and draining lymph node post vaccination in rats
Frontiers in Immunology, 2023 The goal of this study was to utilize a multimodal magnetic resonance imaging (MRI) and positron emission tomography (PET) imaging approach to assess the local innate immune response in skeletal muscle and draining lymph node following vaccination in ...Saaussan Madi, Fang Xie, Kamyar Farhangi, Chih-Yang Hsu, Shih-Hsun Cheng, Tolulope Aweda, Bhasker Radaram, Stephanie Slania, Tammy Lambert, Mary Rambo, Tina Skedzielewski, Austin Cole, Valeriia Sherina, Shannon McKearnan, Hoang Tran, Hasan Alsaid, Minh Doan, Alan H. Stokes, Derek T. O’Hagan, Giulietta Maruggi, Sylvie Bertholet, Stéphane T. Temmerman, Russell Johnson, Beat M. Jucker +23 moredoaj +1 more sourceCircumsporozoite-specific T cell responses in children vaccinated with RTS,S/AS01E and protection against P falciparum clinical malaria. [PDF]
PLoS ONE, 2011 RTS,S/AS01(E) is the lead candidate pre-erythrocytic malaria vaccine. In Phase IIb field trials the safety profile was acceptable and the efficacy was 53% (95%CI 31%-72%) for protecting children against clinical malaria caused by P. falciparum.Ally Olotu, Philippe Moris, Jedidah Mwacharo, Johan Vekemans, Domtila Kimani, Michel Janssens, Oscar Kai, Erik Jongert, Marc Lievens, Amanda Leach, Tonya Villafana, Barbara Savarese, Kevin Marsh, Joe Cohen, Philip Bejon +14 moredoaj +1 more source
